Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monkey
100%
Doxil
100%
Eyelid
100%
Orbicularis Oculi muscle
100%
Nonhuman Primate
25%
Doxorubicin
25%
Skin Injury
25%
Bupivacaine
25%
Blepharospasm
25%
Hyaluronidase
25%
Phase II Trial
12%
Repeated Dose
12%
Phase I Trial
12%
Increased Safety
12%
Cynomolgus Monkey
12%
Species Differences
12%
Histologic Examination
12%
Treatment Schedule
12%
Myofiber
12%
Significant Loss
12%
Muscle Spasm
12%
Injection Site
12%
Treatment Dose
12%
Adjuvant Effect
12%
Muscle Fiber Loss
12%
Bruise
12%
Skin Ulcer
12%
Serial Injection
12%
Liposome-encapsulated
12%
Myotoxic Effect
12%
Medicine and Dentistry
Doxorubicin
100%
Orbicularis Oculi Muscle
100%
Injection
60%
Bupivacaine
20%
Skin Injury
20%
Blepharospasm
20%
Hyaluronidase
20%
Liposome
10%
Venous Ulcer
10%
Phase I Trials
10%
Phase II Trials
10%
Injection Site
10%
Species Difference
10%
Muscle Spasm
10%
Skin Ulcer
10%
Repeated Drug Dose
10%
Adjuvant Therapy
10%
Veterinary Science and Veterinary Medicine
Orbicularis Oculi Muscle
100%
Doxorubicin
100%
Muscle
30%
Bupivacaine
20%
Histologic Examination
10%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Hyaluronidase
20%
Skin Injury
20%
Bupivacaine
20%
Blepharospasm
20%
Phase II Trials
10%
Phase I Trials
10%
Macaca fascicularis
10%
Ulcer
10%
Liposome
10%
Muscle Spasm
10%
Skin Ulcer
10%